Top Page
SS Innovations International
(NASDAQ:SSII)
SS Innovations International (SSII) vs. SPDR S&P 500 ETF (SPY)
SS Innovations International Business Overview & Revenue Model
SS Innovations International Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 18.54M | 20.65M | 5.88M | 1.46M | 0.00 | 0.00 |
| Gross Profit | 6.16M | 8.45M | 713.45K | 489.59K | -18.79K | -37.43K |
| EBITDA | -19.45M | -17.74M | -20.26M | -5.31M | -1.47M | -1.09M |
| Net Income | -22.18M | -19.15M | -20.94M | -5.60M | -1.48M | -1.12M |
Balance Sheet | ||||||
| Total Assets | 63.46M | 42.39M | 25.48M | 8.68M | 428.61K | 317.87K |
| Cash, Cash Equivalents and Short-Term Investments | 15.87M | 466.50K | 7.03M | 1.57M | 405.77K | 160.71K |
| Total Debt | 10.45M | 18.20M | 8.22M | 10.24M | 145.00K | 195.00K |
| Total Liabilities | 22.90M | 28.93M | 11.18M | 11.14M | 287.28K | 1.19M |
| Stockholders Equity | 40.55M | 13.46M | 14.30M | -2.46M | 141.33K | -869.05K |
Cash Flow | ||||||
| Free Cash Flow | -17.16M | -10.16M | -16.34M | -5.78M | -363.03K | -94.54K |
| Operating Cash Flow | -16.94M | -9.50M | -13.57M | -5.56M | -363.03K | -90.54K |
| Investing Cash Flow | 2.67M | -661.48K | -2.30M | -2.74M | 38.15K | -44.00K |
| Financing Cash Flow | 29.09M | 9.43M | 16.73M | 9.29M | 569.95K | 266.77K |
SS Innovations International Technical Analysis
SS Innovations International Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $1.69B | 14.93 | 11.69% | 1.46% | 4.02% | 11.32% | |
60 Neutral | $1.35B | ― | -39.11% | ― | 135.60% | 66.47% | |
55 Neutral | $2.08B | ― | -5.01% | ― | 7.44% | -109.83% | |
51 Neutral | $7.91B | -0.36 | -41.71% | 2.23% | 23.45% | -1.86% | |
50 Neutral | $1.22B | ― | -38.92% | ― | 3.53% | -2309.98% | |
49 Neutral | $863.54M | ― | -111.91% | ― | 25.84% | -47.67% | |
46 Neutral | $1.12B | ― | -261.18% | ― | 17.22% | 1.65% |
SS Innovations International Corporate Events
On August 7, 2025, SS Innovations International reported a significant increase in revenue and gross profit for the second quarter of 2025, driven by higher sales of the SSi Mantra 3 robotic system. The company achieved record quarterly revenue of $10 million, a 121.8% increase from the previous year, and gross profit more than tripled due to expanded gross margins. The company also highlighted several pioneering achievements in robotic surgery, including the world’s first robotic telesurgery for weight loss and intercontinental robotic cardiac telesurgery. SS Innovations’ uplisting to Nasdaq and upcoming regulatory submissions are expected to support its global expansion and continued growth.
On July 23, 2025, Arvind Palaniappan stepped down as the Interim Chief Financial Officer of SS Innovations International. The company is currently searching for a permanent successor, with Dr. Vishwajyoti P. Srivastava, CEO of Asia Pacific, temporarily taking on the CFO responsibilities, indicating a strategic transition phase for the company.
On July 19, 2025, SS Innovations International achieved a milestone by completing the world’s first intercontinental robotic cardiac telesurgery. Dr. Sudhir Srivastava conducted the surgery from Strasbourg, France, to Indore, India, using the SSi Mantra 3 system, demonstrating its advanced capabilities and potential to democratize global cardiac care. This event highlights the company’s innovative approach to overcoming traditional surgical barriers and its commitment to improving medical standards worldwide.
On July 15, 2025, SS Innovations International announced the installation of over 100 SSi Mantra surgical robotic systems across India and six other countries, with more than 5,000 surgeries performed using the system, including 240 cardiac surgeries and 32 telesurgeries. This milestone reflects the growing demand for the SSi Mantra, attributed to its innovative features and cost-effectiveness, and marks a significant step in the company’s goal to democratize access to robotic surgery. The company also plans to seek regulatory approvals in the U.S. and Europe to further expand its market reach.
On July 10, 2025, SS Innovations International announced the successful completion of the world’s first robotic telesurgery for weight loss using their SSi Mantra 3 surgical robotic system. This groundbreaking bariatric telesurgery was conducted over a distance of 560 miles between Gurugram and Indore, India, with Dr. Mohit Bhandari leading the procedure remotely. The surgery demonstrated zero perceptible lag and flawless precision, setting a new standard for remote surgical capabilities. This achievement underscores SS Innovations’ commitment to democratizing robotic surgery by bridging healthcare gaps and providing advanced surgical care to remote regions, thereby revolutionizing healthcare access and equity.
On June 8, 2025, SS Innovations International announced the successful completion of the first robotic cardiac surgery in the Americas and Western Hemisphere using its SSi Mantra 3 surgical robotic system at Interhospital in Guayaquil, Ecuador. This milestone, achieved by Dr. Juan Zuniga, highlights the system’s capabilities in performing minimally invasive procedures with precision, potentially enhancing recovery times and reducing complications, thus strengthening SS Innovations’ position in the surgical robotics industry.
SS Innovations International has released an updated company presentation intended for communication with shareholders and the investment community. The presentation highlights the company’s innovative surgical robotic technologies and its strategic plans for global expansion, particularly into the European and U.S. markets. The announcement underscores the company’s commitment to improving surgical outcomes through advanced technology while maintaining cost-effectiveness and accessibility, potentially impacting its industry positioning and stakeholder interests.
On June 3, 2025, SS Innovations International will ring the opening bell at Nasdaq MarketSite in New York City, marking a significant milestone following the April 2025 uplisting of its common stock to Nasdaq. This event also celebrates the successful completion of over 4,000 robotic surgeries using the SSi Mantra system without complications, highlighting its growing acceptance in India and six other countries, with plans to expand into the European Union and the United States.
On May 27, 2025, SS Innovations International announced that its SSi Mantra surgical robotic system had successfully performed over 4,000 surgeries across more than 100 types without complications. This milestone highlights the system’s quality and acceptance, particularly in India, where the company leads the market. The SSi Mantra is approved in seven countries, and the company is working towards entering the U.S. and EU markets, with regulatory decisions expected in late 2025 and early 2026, respectively.
On May 21, 2025, SS Innovations International appointed Dr. Vishwajyoti P. Srivastava as the Chief Executive Officer for the Asia Pacific region. In his new role, Dr. Srivastava will manage various operational aspects, including marketing and business expansion, with an increased annual base compensation of $300,000.